dantrolene sodium - Søgeresultater

Den Europæiske Union - dansk - EMA (European Medicines Agency)

livensa

warner chilcott deutschland gmbh - testosteron - seksuelle dysfunktioner, psykologiske - køn hormoner og modulatorer af den genitale system, - livensa er indiceret til behandling af hypoaktiv seksuel lyst lidelse (hsdd) i bilateralt oophorectomised og hysterectomised (kirurgisk induceret overgangsalderen) kvinder modtager samtidig østrogenbehandling.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatiske neoplasmer - endokrine terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

erleada

janssen-cilag international nv - apalutamide - prostatiske neoplasmer - endokrine terapi - erleada er anført:i voksne mænd til behandling af ikke-metastatisk kastration resistent prostatakræft (nmcrpc), som er i høj risiko for at udvikle metastatisk sygdom. hos voksne mænd til behandling af metastatisk hormon-følsomme prostatakræft (mhspc) i kombination med androgen deprivation terapi (adt).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

nubeqa

bayer ag - darolutamide - prostatic neoplasmer, kastration-resistent - endokrine terapi - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.